[go: up one dir, main page]

YU1396A - 2,9-disupstituisani purin-6-oni, postupak za njihovo pripremanje i njihova primena u lekovima - Google Patents

2,9-disupstituisani purin-6-oni, postupak za njihovo pripremanje i njihova primena u lekovima

Info

Publication number
YU1396A
YU1396A YU1396A YU1396A YU1396A YU 1396 A YU1396 A YU 1396A YU 1396 A YU1396 A YU 1396A YU 1396 A YU1396 A YU 1396A YU 1396 A YU1396 A YU 1396A
Authority
YU
Yugoslavia
Prior art keywords
purin
disupstituted
medicines
procedure
preparation
Prior art date
Application number
YU1396A
Other languages
English (en)
Inventor
Ulrich Niewohner
Erwin Bishoff
Helmuth Schutz
Elisabeth Perzobron
Matthias Schramm
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of YU1396A publication Critical patent/YU1396A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

2,9-disupstituisani purin-6-oni, formule I, u kojoj A, R1, R2, R3, R4 imaju značenja data u 1. patentnom zahtevu, pripremaju se kada se u prvom stupnju aciluju odgovarajuće supstituisani aminoimidazoli, pa se zatim ciklizuju u purin. Novi 2,9-disupstituisani purin-6-oni mogu da se upotrebe kao delotvorne supstance u lekovima, naročito za lečenje zapaljivih procesa, tromboembolijskih, srčanih i oboljenja krvotoka, i oboljenja urogenitalnog sistema.
YU1396A 1995-01-19 1996-01-12 2,9-disupstituisani purin-6-oni, postupak za njihovo pripremanje i njihova primena u lekovima YU1396A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19501482A DE19501482A1 (de) 1995-01-19 1995-01-19 2,9-disubstituierte Purin-6-one

Publications (1)

Publication Number Publication Date
YU1396A true YU1396A (sh) 1999-03-04

Family

ID=7751830

Family Applications (1)

Application Number Title Priority Date Filing Date
YU1396A YU1396A (sh) 1995-01-19 1996-01-12 2,9-disupstituisani purin-6-oni, postupak za njihovo pripremanje i njihova primena u lekovima

Country Status (31)

Country Link
US (1) US5861404A (sh)
EP (1) EP0722944A1 (sh)
JP (1) JPH08231545A (sh)
KR (1) KR960029334A (sh)
CN (1) CN1135485A (sh)
AR (1) AR002953A1 (sh)
AU (1) AU4097996A (sh)
BG (1) BG61728B1 (sh)
BR (1) BR9600147A (sh)
CA (1) CA2167353A1 (sh)
CO (1) CO4700523A1 (sh)
CZ (1) CZ16696A3 (sh)
DE (1) DE19501482A1 (sh)
EE (1) EE9600018A (sh)
FI (1) FI960225A7 (sh)
HR (1) HRP960007A2 (sh)
HU (1) HUP9600106A3 (sh)
IL (1) IL116769A (sh)
MA (1) MA23778A1 (sh)
NO (1) NO960223L (sh)
NZ (1) NZ280830A (sh)
PE (1) PE64996A1 (sh)
PL (1) PL312354A1 (sh)
SG (1) SG50401A1 (sh)
SK (1) SK8096A3 (sh)
SV (1) SV1996000006A (sh)
TN (2) TNSN96007A1 (sh)
TR (1) TR199600028A2 (sh)
TW (1) TW314519B (sh)
YU (1) YU1396A (sh)
ZA (1) ZA96398B (sh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19529102A1 (de) * 1995-08-08 1997-02-13 Kummer Horst Dieter Verwendung von PDE-Inhibitoren bei der Behandlung von Harnblasenerkrankungen
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
EP0999211A4 (en) * 1997-07-15 2001-09-19 Japan Energy Corp NEW PURINE DERIVATIVES AND THEIR MEDICAL APPLICATION
CA2309350C (en) * 1997-11-12 2007-04-03 Mitsubishi Chemical Corporation Purine derivatives and medicaments comprising the same as active ingredient
AU1688599A (en) * 1998-01-05 1999-07-26 Eisai Co. Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
KR100747106B1 (ko) 1999-05-11 2007-08-08 미쯔비시 가가꾸 가부시끼가이샤 퓨린 유도체 이수화물, 이를 유효성분으로 함유하는 의약및 이의 제조 중간체
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
US7501409B2 (en) * 2000-09-06 2009-03-10 Mitsubishi Tanabe Pharma Corporation Preparations for oral administration
US7927623B2 (en) * 2001-02-15 2011-04-19 Mitsubishi Tanabe Pharma Corporation Tablets quickly disintegrated in oral cavity
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
CN102742513A (zh) * 2012-07-17 2012-10-24 南京熊猫机电制造有限公司 一种喂食栏装置
JP6687550B2 (ja) 2014-06-23 2020-04-22 セルジーン コーポレイション 肝疾患又は肝機能異常を治療するためのアプレミラスト
AU2020256166A1 (en) 2019-04-02 2021-10-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5
JP7385467B2 (ja) * 2019-12-26 2023-11-22 キッセイ薬品工業株式会社 ヒポキサンチン化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
IL76546A (en) * 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
AR002953A1 (es) 1998-05-27
SG50401A1 (en) 1998-07-20
TR199600028A2 (tr) 1996-08-21
JPH08231545A (ja) 1996-09-10
DE19501482A1 (de) 1996-07-25
KR960029334A (ko) 1996-08-17
TW314519B (sh) 1997-09-01
BG100292A (bg) 1996-07-31
SV1996000006A (es) 1996-10-29
TNSN96007A1 (fr) 2005-03-15
EE9600018A (et) 1996-08-15
NO960223D0 (no) 1996-01-18
US5861404A (en) 1999-01-19
EP0722944A1 (de) 1996-07-24
BG61728B1 (bg) 1998-04-30
CA2167353A1 (en) 1996-07-20
IL116769A0 (en) 1996-05-14
NO960223L (no) 1996-07-22
FI960225L (fi) 1996-07-20
CN1135485A (zh) 1996-11-13
HU9600106D0 (en) 1996-03-28
CZ16696A3 (en) 1996-08-14
ZA96398B (en) 1996-08-28
SK8096A3 (en) 1996-08-07
AU4097996A (en) 1996-07-25
FI960225A0 (fi) 1996-01-17
PE64996A1 (es) 1997-03-09
HUP9600106A3 (en) 1998-04-28
CO4700523A1 (es) 1998-12-29
NZ280830A (en) 1998-04-27
PL312354A1 (en) 1996-07-22
TNSN96006A1 (fr) 2005-03-15
HUP9600106A2 (en) 1997-05-28
FI960225A7 (fi) 1996-07-20
IL116769A (en) 1998-12-06
MA23778A1 (fr) 1996-10-01
HRP960007A2 (en) 1998-02-28
BR9600147A (pt) 1998-01-06

Similar Documents

Publication Publication Date Title
YU1396A (sh) 2,9-disupstituisani purin-6-oni, postupak za njihovo pripremanje i njihova primena u lekovima
NO995006L (no) Nye forbindelser
RU95110938A (ru) Производные 1-(2-оксоацетил)пиперидин-2-карбоновых кислот, фармацевтическая композиция, способ лечения, способ получения
MY124122A (en) Heterocyclic derivatives
CA2148928A1 (en) Pharmacologically active pyridine derivatives and processes for the preparation thereof
NO304793B1 (no) nor-gallesyrederivater, og anvendelse av dem for fremstilling av legemiddel
NO20002788L (no) Nye forbindelser
FR2686084B1 (fr) Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
FI900307A0 (fi) Menetelmä valmistaa terapeuttisesti aktiivista 3-/3-okso-(2,3)-dihydropyridatsin-6-yyli/-2-fenyyli-pyratsolo/1,5-a/pyridiinijohdannaisia
YU1496A (sh) 2,8-disupstituisani hinazolinoni, postupak za njihovo dobijanje i njihova primena
DE3783356D1 (de) Benzimidazolderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate.
ATE235893T1 (de) Orale zubereitung enthaltend zonula occludens toxin und einen biologisch aktiven wirkstoff sowie deren verwendung
MA26435A1 (fr) Derives de benzylamine amido-substitues, leurs derives precurseurs de medicaments, leur procede de preparation, compositions pharmaceutiques les contenant et methode de traitement les utilisant.
BG101715A (bg) Тетрациклени спиросъединения,метод за тяхното получаване и приложението им като 5нт долу 1d рецепторни антагонисти
FI946073A0 (fi) Vitamiini D-sarjan, 20-asemassa modifioituja johdannaisia, menetelmä tällaisten johdannaisten valmistamiseksi, menetelmässä käytettäviä välituotteita, mainittuja johdannaisia sisältäviä farmaseuttisia valmisteita ja johdannaisten käyttö lääkeaineiden valmistamiseen
DE3863366D1 (de) Antibiotikum vermisporin, verfahren zu dessen herstellung und dasselbe als aktiver antibakterieller wirkstoff enthaltende pharmazeutische zusammensetzung.
DE69125715D1 (de) Heterozyklische verbindungen
CA2187409A1 (en) Stable Crystalline Tetrahydrofolic Acid Salts
ATE259369T1 (de) Neue geranylgeranylderivate, verfahren zu deren herstellung und entsprechende pharmazeutische zusammensetzungen
NO893135L (no) Fremgangsmaate for fremstilling av n-2,3-butadienyl tri- og tetraaminoalkanderivater.
NZ510153A (en) Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals
ATE94764T1 (de) Nasal applizierbares arzneimittel, verfahren zu seiner herstellung und seine verwendung.
CA2195747A1 (en) New 3-substituted 3h-2,3-benzodiazepine derivatives, their preparation and use as medicaments
ATE32897T1 (de) Pyrazolo(3,4,5-kl)acridinderivate, pharmazeutische zubereitungen die sie enthalten und verfahren zu ihrer herstellung.
ATE23719T1 (de) Rifamycinderivate, herstellung und diese enthaltende pharmazeutische zubereitungen.